Regulatory environment for allergen-specific immunotherapy.
about
Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity doseManagement of the polyallergic patient with allergy immunotherapy: a practice-based approachPeamaclein--a new peach allergenic protein: similarities, differences and misleading features compared to Pru p 3.A multi-allergen standard for the calibration of immunoassays: CREATE principles applied to eight purified allergensRegulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach.Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus reportSublingual allergen immunotherapy: mode of action and its relationship with the safety profile.Molecular approaches to allergen standardization.Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy.Standardization and Regulation of Allergen Products in the European Union.Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper.300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis.Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products.AIT (allergen immunotherapy): a model for the "precision medicine".Allergen immunotherapy on the way to product-based evaluation-a WAO statement.Allergen-specific immunotherapy: current concepts and future directions.Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.Standardization of allergen products: 2. Detailed characterization of GMP-produced recombinant Phl p 5.0109 as European Pharmacopoeia reference standard.
P2860
Q26772069-D8AFFEF2-E9D1-4909-9AE9-A24211420082Q26772200-647F73C6-371D-4A56-8FB6-3C4EB9BF5154Q30583714-F91D326B-05CB-49C6-BD06-895E4C4B08BCQ35670288-69D84209-5153-4E5A-88D8-23318E4FD086Q36834860-952DBDE5-7313-4ACC-A0D6-0E9E26D98426Q37696401-B14B970B-A1E8-4E48-83D9-E7514FEBCA6CQ37965770-F2FAD51E-8DF8-4B9F-9BA6-2643024592E7Q38022184-337DFD18-79CC-4DAD-A525-D1B376AF340BQ38247821-8CEFA53A-5194-4443-927A-4E7B26FA13A5Q38621313-F2D2E746-8663-4E1A-A36E-306EBFE648DFQ38732578-37533900-6C03-4190-A0E5-B1919CF49924Q38765929-2B6FEB2D-4AB5-4D81-ACD0-6F0F788D7AD1Q38955332-14A93C20-4591-4B0C-B62A-C0A8F6468703Q40108188-4594B5E3-D187-443C-A242-AB3809BBB609Q41134553-F68F187F-3799-42CA-A1B4-659AECE10A3DQ43249691-6F5711BD-2F86-4ABA-8426-E44CE334E44DQ43709615-FACA8D71-1150-4197-9F0D-40E046AFC681Q47660259-26F418E1-3FE7-4843-B43A-901FAB0A063BQ53242840-56267B21-38DC-4FB7-B11C-8FD97F97FD3F
P2860
Regulatory environment for allergen-specific immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulatory environment for allergen-specific immunotherapy.
@en
Regulatory environment for allergen-specific immunotherapy.
@nl
type
label
Regulatory environment for allergen-specific immunotherapy.
@en
Regulatory environment for allergen-specific immunotherapy.
@nl
prefLabel
Regulatory environment for allergen-specific immunotherapy.
@en
Regulatory environment for allergen-specific immunotherapy.
@nl
P2093
P2860
P1433
P1476
Regulatory environment for allergen-specific immunotherapy.
@en
P2093
P2860
P304
P356
10.1111/J.1398-9995.2011.02552.X
P577
2011-02-03T00:00:00Z